Hidaka Isao, Hino Keisuke, Korenaga Masaaki, Gondo Toshikazu, Nishina Sohji, Ando Miye, Okuda Michiari, Sakaida Isao
Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Liver Int. 2007 Aug;27(6):845-53. doi: 10.1111/j.1478-3231.2007.01492.x.
BACKGROUND/AIM: Stronger Neo-Minophagen C (SNMC), a glycyrrhizin-containing preparation, has been used as a treatment for chronic hepatitis for more than 30 years in Japan, and shown to be effective in preventing the development of hepatocellular carcinoma in chronic hepatitis C patients, but its underlying mechanisms remain elusive. The aim of this study was to investigate if SNMC had an anti-oxidative effect, as oxidative stress has been proposed to be one of the mechanisms of liver injury in hepatitis C virus (HCV)-associated chronic liver diseases.
The protective effect of SNMC against carbon tetrachloride (CCl4)-induced liver injury was examined using transgenic mice expressing the HCV polyprotein.
A small dose of CCl4 (10 microl/kg of body weight) significantly increased the serum alanine aminotransferase (ALT) level and hepatic malondialdehyde content, decreased hepatic reduced glutathione (GSH) content and induced ultrastructural alterations of hepatic mitochondria in transgenic mice, but not in nontransgenic mice. A single SNMC treatment equivalent to a clinical dose significantly restored the serum ALT level and hepatic malondialdehyde and GSH contents, attenuated the ultrastructural alterations of hepatic mitochondria, and increased mRNA expression of gamma-glutamylcysteine synthetase (gamma-GCS).
Transgenic mice expressing the HCV polyprotein are abnormally vulnerable to oxidative stress. SNMC protects hepatocytes against CCl4-induced oxidative stress and mitochondrial injury in the presence of HCV proteins by restoring depleted cellular GSH.
背景/目的:强力新(SNMC)是一种含甘草酸制剂,在日本已用于治疗慢性肝炎30多年,且已证明对预防丙型肝炎慢性患者肝细胞癌的发生有效,但其潜在机制仍不清楚。本研究的目的是调查SNMC是否具有抗氧化作用,因为氧化应激被认为是丙型肝炎病毒(HCV)相关慢性肝病肝损伤的机制之一。
使用表达HCV多聚蛋白的转基因小鼠,检测SNMC对四氯化碳(CCl4)诱导的肝损伤的保护作用。
小剂量的CCl4(10微升/千克体重)显著增加转基因小鼠血清丙氨酸转氨酶(ALT)水平和肝脏丙二醛含量,降低肝脏还原型谷胱甘肽(GSH)含量,并诱导肝脏线粒体超微结构改变,但对非转基因小鼠无此作用。单次给予相当于临床剂量的SNMC可显著恢复血清ALT水平以及肝脏丙二醛和GSH含量,减轻肝脏线粒体超微结构改变,并增加γ-谷氨酰半胱氨酸合成酶(γ-GCS)的mRNA表达。
表达HCV多聚蛋白的转基因小鼠对氧化应激异常敏感。SNMC通过恢复耗尽的细胞内GSH,保护肝细胞免受CCl4诱导的氧化应激和HCV蛋白存在时的线粒体损伤。